GBD 2023 Power Kidney Illness CollaboratorsGlobal, regional, and nationwide burden of continual kidney illness in adults, 1990–2023, and its attributable danger components: a scientific evaluation for the International Burden of Illness Research 2023. Lancet 406, 2461–2482 (2025).
Gansevoort, R. T. et al. Power kidney illness and cardiovascular danger: epidemiology, mechanisms, and prevention. Lancet 382, 339–352 (2013).
Jankowski, J., Floege, J., Fliser, D., Böhm, M. & Marx, N. Heart problems in continual kidney illness: pathophysiological insights and therapeutic choices. Circulation 143, 1157–1172 (2021).
Li, X. & Lindholm, B. Cardiovascular danger prediction in continual kidney illness. Am. J. Nephrol. 53, 730–739 (2022).
Zoccali, C. et al. The autonomic nervous system and irritation in continual kidney illness. Nephrol. Dial. Transpl. 40, 1470–1482 (2025).
Mihai, S. et al. Irritation-Associated mechanisms in continual kidney illness prediction, development, and end result. J. Immunol. Res. 2018, 2180373 (2018).
Amdur, R. L. et al. Irritation and development of CKD: the CRIC research. Clin. J. Am. Soc. Nephrol. 11, 1546–1556 (2016).
Tonelli, M., Sacks, F., Pfeffer, M., Jhangri, G. S. & Curhan, G. Ldl cholesterol, recurrent occasions trial I. Biomarkers of irritation and development of continual kidney illness. Kidney Int. 68, 237–245 (2005).
Tuttle, Ok. R. et al. Molecular mechanisms and therapeutic targets for diabetic kidney illness. Kidney Int. 102, 248–260 (2022).
Furman, D. et al. Power irritation within the etiology of illness throughout the life span. Nat. Med. 25, 1822–1832 (2019).
Ferrucci, L. & Fabbri, E. Inflammageing: continual irritation in ageing, heart problems, and frailty. Nat. Rev. Cardiol. 15, 505–522 (2018).
Gupta, J. et al. Affiliation between albuminuria, kidney operate, and inflammatory biomarker profile in CKD in CRIC. Clin. J. Am. Soc. Nephrol. 7, 1938–1946 (2012).
Navarro, J. F., Mora, C., Maca, M. & Garca, J. Inflammatory parameters are independently related to urinary albumin in sort 2 diabetes mellitus. Am. J. Kidney Dis. 42, 53–61 (2003).
Shlipak, M. G. et al. Elevations of inflammatory and procoagulant biomarkers in aged individuals with renal insufficiency. Circulation 107, 92 (2003).
Upadhyay, A. et al. Irritation, kidney operate and albuminuria within the Framingham Offspring cohort. Nephrol. Dial. Transpl. 26, 920–926 (2011).
Hiramoto, J. S. et al. Irritation and coagulation markers and kidney operate decline: the Multi-Ethnic Research of Atherosclerosis (MESA). Am. J. Kidney Dis. 60, 225–232 (2012).
Stenvinkel, P. et al. Robust affiliation between malnutrition, irritation, and atherosclerosis in continual renal failure. Kidney Int. 55, 1899–1911 (1999).
Yilmaz, M. I. et al. The connection between IL-10 ranges and cardiovascular occasions in sufferers with CKD. Clin. J. Am. Soc. Nephrol. 9, 1207–1216 (2014).
Snaedal, S. et al. Comorbidity and acute medical occasions as determinants of C-reactive protein variation in hemodialysis sufferers: implications for affected person survival. Am. J. Kidney Dis. 53, 1024–1033 (2009).
Meuwese, C. L., Stenvinkel, P., Dekker, F. W. & Carrero, J. J. Monitoring of irritation in sufferers on dialysis: forewarned is forearmed. Nat. Rev. Nephrol. 7, 166–176 (2011).
Mazhar, F. et al. Systemic irritation and well being outcomes in sufferers receiving therapy for atherosclerotic heart problems. Eur. Coronary heart J. 45, 4719–4730 (2024).
Mazhar, F. et al. Systemic irritation and the dangers of hostile kidney outcomes in adults with atherosclerotic heart problems. Am. J. Kidney Dis. 86, 314–323.e1 (2025).
Bazeley, J. et al. C-reactive protein and prediction of 1-year mortality in prevalent hemodialysis sufferers. Clin. J. Am. Soc. Nephrol. 6, 2452–2461 (2011).
Meuwese, C. L. et al. Trimestral variations of C-reactive protein, interleukin-6 and tumour necrosis factor-α are equally related to survival in haemodialysis sufferers. Nephrol. Dial. Transpl. 26, 1313–1318 (2011).
Kalantar-Zadeh, Ok., Ikizler, T. A., Block, G., Avram, M. M. & Kopple, J. D. Malnutrition–irritation advanced syndrome in dialysis sufferers: causes and penalties. Am. J. Kidney Dis. 42, 864–881 (2003).
Kalantar-Zadeh, Ok., Brennan, M. L. & Hazen, S. L. Serum myeloperoxidase and mortality in upkeep hemodialysis sufferers. Am. J. Kidney Dis. 48, 59–68 (2006).
Poesen, R. et al. Associations of soluble CD14 and endotoxin with mortality, heart problems, and development of kidney illness amongst sufferers with CKD. Clin. J. Am. Soc. Nephrol. 10, 1525–1533 (2015).
Barreto, D. V. et al. Plasma interleukin-6 is independently related to mortality in each hemodialysis and pre-dialysis sufferers with continual kidney illness. Kidney Int. 77, 550–556 (2010).
Menon, V. et al. C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in continual kidney illness. Kidney Int. 68, 766–772 (2005).
Vickery, S. et al. Prognostic worth of cardiac biomarkers for dying in a non-dialysis continual kidney illness inhabitants. Nephrol. Dial. Transpl. 23, 3546–3553 (2008).
Honda, H. et al. Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, heart problems, and mortality in sufferers with ESRD. Am. J. Kidney Dis. 47, 139–148 (2006).
Mensah, G. A. et al. Irritation and heart problems: 2025 ACC Scientific Assertion: a report of the American Faculty of Cardiology. J. Am. Coll. Cardiol. 29, S0735–S1097 (2025).
Mach, F., Roeters van Lennep, J. E. & Koskinas, Ok. C. The ‘10 commandments’ for the 2025 centered replace of the 2019 ESC/EAS pointers for the administration of dyslipidaemias. Eur. Coronary heart J. 47, 658–659 (2026).
Blumenthal, R. S. et al. ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Administration of Dyslipidemia: a report of the American Faculty of Cardiology/American Coronary heart Affiliation Joint Committee on Medical Observe Pointers. Circulation 153, e1154–e1276 (2026).
Zoccali, C., Tripepi, G. & Mallamaci, F. Dissecting irritation in ESRD: do cytokines and C-reactive protein have a complementary prognostic worth for mortality in dialysis sufferers? J. Am. Soc. Nephrol. 17, S169–S173 (2006).
Gupta, J. et al. Affiliation between irritation and cardiac geometry in continual kidney illness: findings from the CRIC research. PLoS ONE 10, e0124772 (2015).
Yilmaz, M. I. et al. Vascular well being, systemic irritation and progressive discount in kidney operate; medical determinants and influence on cardiovascular outcomes. Nephrol. Dial. Transpl. 26, 3537–3543 (2011).
Herder, C. et al. Chemokines and incident coronary coronary heart illness: outcomes from the MONICA/KORA Augsburg case-cohort research, 1984–2002. Arterioscler. Thromb. Vasc. Biol. 26, 2147–2152 (2006).
Prapiadou, S. et al. Proteogenomic knowledge integration reveals CXCL10 as a doubtlessly downstream causal mediator for IL-6 signaling on atherosclerosis. Circulation 149, 669–683 (2024).
Mc Causland, F. R. et al. C-reactive protein and danger of ESRD: outcomes from the trial to scale back cardiovascular occasions with aranesp remedy (TREAT). Am. J. Kidney Dis. 68, 873–881 (2016).
Koshino, A. et al. Interleukin-6 and cardiovascular and kidney outcomes in sufferers with sort 2 diabetes: new insights from CANVAS. Diabetes Care 45, 2644–2652 (2022).
Wu, T. H., Wu, S. C., Huang, T. P., Yu, C. L. & Tsai, C. Elevated excretion of tumor necrosis issue alpha and interleukin 1 beta in urine from sufferers with IgA nephropathy and Schönlein-Henoch purpura. Nephron 74, 79–88 (1996).
Chen, Y. M., Lin, S. L., Chiang, W. C., Wu, Ok. D. & Tsai, T. J. Pentoxifylline ameliorates proteinuria by way of suppression of renal monocyte chemoattractant protein-1 in sufferers with proteinuric major glomerular ailments. Kidney Int. 69, 1410–1415 (2006).
Morii, T. et al. Elevated urinary excretion of monocyte chemoattractant protein-1 in proteinuric renal ailments. Ren. Fail. 25, 439–444 (2003).
Sarnak, M. J. et al. Serum C-reactive protein and leptin as predictors of kidney illness development within the Modification of Weight loss plan in Renal Illness Research. Kidney Int. 62, 2208–2215 (2002).
Fu, E. L. et al. Excessive-sensitivity C-reactive protein and the danger of continual kidney illness development or acute kidney harm in post-myocardial infarction sufferers. Am. Coronary heart J. 216, 20–29 (2019).
Tuttle, Ok. R. et al. An actual-world cohort research of the dangers of kidney failure and dying in diabetes. Clin. J. Am. Soc. Nephrol. 21, 83–94 (2026).
Fried, L. et al. Inflammatory and prothrombotic markers and the development of renal illness in aged people. J. Am. Soc. Nephrol. 15, 3184–3191 (2004).
Agboola, O. J. et al. The function of irritation in longitudinal renal operate decline and incident continual kidney illness: the multi-ethnic research of atherosclerosis. Eur. J. Prev. Cardiol. 33, 718–728 (2026).
Bradbury, B. D. et al. Influence of elevated C-reactive protein ranges on erythropoiesis- stimulating agent (ESA) dose and responsiveness in hemodialysis sufferers. Nephrol. Dial. Transpl. 24, 919–925 (2009).
Karaboyas, A. et al. Irritation and erythropoiesis-stimulating agent response in hemodialysis sufferers: a self-matched longitudinal research of anemia administration within the Dialysis Outcomes and Observe Patterns Research (DOPPS). Kidney Med. 2, 286–296 (2020).
Kovesdy, C. P. How can erythropoietin-stimulating agent use be diminished in continual dialysis sufferers?: can discount of irritation enhance ESA dose response? Semin. Dial. 26, 540–542 (2013).
Carrero, J. J. et al. Etiology of the protein-energy losing syndrome in continual kidney illness: a consensus assertion from the Worldwide Society of Renal Diet and Metabolism (ISRNM). J. Ren. Nutr. 23, 77–90 (2013).
Deger, S. M. et al. Systemic irritation is related to exaggerated skeletal muscle protein catabolism in upkeep hemodialysis sufferers. JCI Perception 2, e95185 (2017).
Wang, X. H. & Mitch, W. E. Mechanisms of muscle losing in continual kidney illness. Nat. Rev. Nephrol. 10, 504–516 (2014).
Snaedal, S. Dialysis modality and dietary standing are related to variability of inflammatory markers. Nephrol. Dial. Transpl. 31, 1320–1327 (2016).
Stenvinkel, P. et al. Are there two sorts of malnutrition in continual renal failure? Proof for relationships between malnutrition, irritation and atherosclerosis (MIA syndrome). Nephrol. Dial. Transpl. 15, 953–608 (2000).
Kalantar-Zadeh, Ok., Block, G., Humphreys, M. H. & Kopple, J. D. Reverse epidemiology of cardiovascular danger components in upkeep dialysis sufferers. Kidney Int. 63, 793–808 (2003).
Rambod, M., Kovesdy, C. & Kalantar-Zadeh, Ok. Malnutrition–Irritation Rating for danger stratification of sufferers with CKD: is it the promised gold normal?Nat. Rev. Nephrol. 4, 354–355 (2008).
Libby, P. & Ridker, P. M. Irritation and atherothrombosis: from inhabitants biology and bench analysis to medical apply. J. Am. Coll. Cardiol. 48, A33–A46 (2006).
Bondareva, O. et al. Single-cell profiling of vascular endothelial cells reveals progressive organ-specific vulnerabilities throughout weight problems. Nat. Metab. 4, 1591–1610 (2022).
Zoccali, C. & Mallamaci, F. Innate immunity system in sufferers with cardiovascular and kidney illness. Circ. Res. 132, 915–932 (2023).
Kurts, C., Ginhoux, F. & Panzer, U. Kidney dendritic cells: basic biology and practical roles in well being and illness. Nat. Rev. Nephrol. 16, 391–407 (2020).
Wang, Y. H. & Zhang, Y. G. Kidney and innate immunity. Immunol. Lett. 183, 73–78 (2017).
Leemans, J. C., Kors, L., Anders, H. J. & Florquin, S. Sample recognition receptors and the inflammasome in kidney illness. Nat. Rev. Nephrol. 10, 398–414 (2014).
Tang, S. C. W. & Yiu, W. H. Innate immunity in diabetic kidney illness. Nat. Rev. Nephrol. 16, 206–222 (2020).
Bhargava, R., Li, H. & Tsokos, G. C. Pathogenesis of lupus nephritis: the contribution of immune and kidney resident cells. Curr. Opin. Rheumatol. 35, 107–116 (2023).
Tsokos, G. C. et al. The immunoregulatory roles of non-haematopoietic cells within the kidney. Nat. Rev. Nephrol. 20, 206–217 (2024).
Lin, M. & Tang, S. C. Toll-like receptors: sensing and reacting to diabetic harm within the kidney. Nephrol. Dial. Transpl. 29, 746–754 (2014).
De Nardo, D. Toll-like receptors: activation, signalling and transcriptional modulation. Cytokine 74, 181–189 (2015).
Scherberich, J. E. & Nockher, W. A. Blood monocyte phenotypes and soluble endotoxin receptor CD14 in systemic inflammatory ailments and sufferers with continual renal failure. Nephrol. Dial. Transpl. 15, 574–578 (2000).
Ranoa, D. R. E., Kelley, S. L. & Tapping, R. I. Human lipopolysaccharide-binding protein (LBP) and CD14 independently ship triacylated lipoproteins to Toll-like receptor 1 (TLR1) and TLR2 and improve formation of the ternary signaling advanced. J. Biol. Chem. 288, 9729–9741 (2013).
Lin, M. et al. Toll-like receptor 4 promotes tubular irritation in diabetic nephropathy. J. Am. Soc. Nephrol. 23, 86–102 (2012).
Wendt, T. et al. Glucose, glycation, and RAGE: implications for amplification of mobile dysfunction in diabetic nephropathy. J. Am. Soc. Nephrol. 14, 1383–1395 (2003).
Noh, H. & King, G. L. The function of protein kinase C activation in diabetic nephropathy. Kidney Int. Suppl. 106, S49–S53 (2007).
Meek, R. L. et al. Glomerular cell dying and irritation with high-protein weight loss plan and diabetes. Nephrol. Dial. Transpl. 28, 1711–1720 (2013).
Tuttle, Ok. R., Anderberg, R. J., Cooney, S. Ok. & Meek, R. L. Oxidative stress mediates protein kinase C activation and superior glycation finish product formation in a mesangial cell mannequin of diabetes and excessive protein weight loss plan. Am. J. Nephrol. 29, 171–180 (2009).
Berthier, C. C. et al. Enhanced expression of Janus kinase-signal transducer and activator of transcription pathway members in human diabetic nephropathy. Diabetes 58, 469–477 (2009).
Anderberg, R. J. et al. Serum amyloid A and irritation in diabetic kidney illness and podocytes. Lab. Make investments. 95, 250–262 (2015).
Tanji, N. et al. Expression of superior glycation finish merchandise and their mobile receptor RAGE in diabetic nephropathy and nondiabetic renal illness. J. Am. Soc. Nephrol. 11, 1656–1666 (2000).
Mulay, S. R. Multifactorial capabilities of the inflammasome element NLRP3 in pathogenesis of continual kidney ailments. Kidney Int. 96, 58–66 (2019).
Liu, D., Zeng, X., Li, X., Mehta, J. L. & Wang, X. Function of NLRP3 inflammasome within the pathogenesis of cardiovascular ailments. Primary. Res. Cardiol. 113, 5 (2017).
Shahzad, Ok. Caspase-1, however not caspase-3, promotes diabetic nephropathy. J. Am. Soc. Nephrol. 27, 2270–2275 (2016).
Shahzad, Ok. et al. Podocyte-specific Nlrp3 inflammasome activation promotes diabetic kidney illness. Kidney Int. 102, 766–779 (2022).
Takeda, Ok., Noguchi, T., Naguro, I. & Ichijo, H. Apoptosis signal-regulating kinase 1 in stress and immune response. Annu. Rev. Pharmacol. Toxicol. 48, 199–225 (2008).
Thakur, D. et al. Up to date insights on ASK1 signaling: mechanisms, regulation, and therapeutic potential in ailments. Mol. Cell Biochem. 480, 5267–5296 (2025).
Liles, J. T. et al. ASK1 contributes to fibrosis and dysfunction in fashions of kidney illness. J. Clin. Make investments. 128, 4485–4500 (2018).
Feigerlová, E. & Battaglia-Hsu, S. F. IL-6 signaling in diabetic nephropathy: from pathophysiology to therapeutic views. Cytokine Progress Issue. Rev. 37, 57–65 (2017).
Ridker, P. M. & Rane, M. Interleukin-6 signaling and anti-interleukin-6 therapeutics in heart problems. Circ. Res. 128, 1728–1746 (2021).
Jones, S. A. & Jenkins, B. J. Latest insights into focusing on the IL-6 cytokine household in inflammatory ailments and most cancers. Nat. Rev. Immunol. 18, 773–789 (2018).
Rose-John, S., Scheller, J., Elson, G. & Jones, S. A. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: function in irritation and most cancers. J. Leukoc. Biol. 80, 227–236 (2006).
Coletta, I. et al. Selective induction of MCP-1 in human mesangial cells by the IL-6/sIL-6R advanced. Exp. Nephrol. 8, 37–43 (2000).
Nechemia-Arbely, Y. et al. IL-6/IL-6R axis performs a essential function in acute kidney harm. J. Am. Soc. Nephrol. 19, 1106–1115 (2008).
Kim, D. I. & Park, S. H. Sequential signaling cascade of IL-6 and PGC-1α is concerned in excessive glucose-induced podocyte loss and progress arrest. Biochem. Biophys. Res. Commun. 435, 702–707 (2013).
Privratsky, J. R. et al. A macrophage-endothelial immunoregulatory axis ameliorates septic acute kidney harm. Kidney Int. 103, 514–528 (2023).
Chen, W. et al. Blocking interleukin-6 trans-signaling protects towards renal fibrosis by suppressing STAT3 activation. Theranostics 9, 3980–3991 (2019).
Marrero, M. B., Banes-Berceli, A. Ok., Stern, D. M. & Eaton, D. C. Function of the JAK/STAT signaling pathway in diabetic nephropathy. Am. J. Physiol. Renal Physiol. 290, F762–F768 (2006).
Roy, P., Orecchioni, M. & Ley, Ok. How the immune system shapes atherosclerosis: roles of innate and adaptive immunity. Nat. Rev. Immunol. 22, 251–265 (2022).
Libby, P., Lichtman, A. H. & Hansson, G. Ok. Immune effector mechanisms implicated in atherosclerosis: from mice to people. Immunity 38, 1092–1104 (2013).
Libby, P., Pasterkamp, G., Crea, F. & Jang, I. Ok. Reassessing the mechanisms of acute coronary syndromes. Circ. Res. 124, 150–160 (2019).
Libby, P. Irritation in the course of the life cycle of the atherosclerotic plaque. Cardiovasc. Res. 117, 2525–2536 (2021).
Hansson, G. Ok. Irritation, atherosclerosis, and coronary artery illness. N. Engl. J. Med. 352, 1685–1695 (2005).
Rai, V. & Agrawal, D. Ok. The function of damage- and pathogen-associated molecular patterns in inflammation-mediated vulnerability of atherosclerotic plaques. Can. J. Physiol. Pharmacol. 95, 1245–1253 (2017).
Roesner, C. et al. Variations of inflammatory cytokine profile in sufferers with weak plaque: a coronary CTA research. Atherosclerosis 350, 25–32 (2022).
Yuki, H. et al. Coronary irritation and plaque vulnerability: a coronary computed tomography and optical coherence tomography research. Circ. Cardiovasc. Imaging 16, e014959 (2023).
Fernandez, D. M. et al. Single-cell immune panorama of human atherosclerotic plaques. Nat. Med. 25, 1576–1588 (2019).
Chen, G. Y. & Nuñez, G. Sterile irritation: sensing and reacting to break. Nat. Rev. Immunol. 10, 826–837 (2010).
Simons, Ok. H. et al. The protecting function of Toll-like receptor 3 and type-I interferons within the pathophysiology of vein graft illness. J. Mol. Cell Cardiol. 121, 16–24 (2018).
Birks, E. J. et al. Elevated Toll-like receptor 4 within the myocardium of sufferers requiring left ventricular help gadgets. J. Coronary heart Lung Transpl. 23, 228–235 (2004).
Que, X. et al. Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice. Nature 558, 301–306 (2018).
Chen, H., Zhang, R. Q., Wei, X. G., Ren, X. M. & Gao, X. Q. Mechanism of TLR-4/NF-κB pathway in myocardial ischemia reperfusion harm of mouse. Asian Pac. J. Trop. Med. 9, 503–507 (2016).
Toldo, S. & Abbate, A. The function of the NLRP3 inflammasome and pyroptosis in cardiovascular ailments. Nat. Rev. Cardiol. 21, 219–237 (2024).
Chevriaux, A. et al. Cathepsin B is required for NLRP3 inflammasome activation in macrophages, by way of NLRP3 interplay. Entrance. Cell Dev. Biol. 8, 167 (2020).
Matzinger, P. The hazard mannequin: a renewed sense of self. Science 296, 301–305 (2002).
Loppnow, H. & Libby, P. Grownup human vascular endothelial cells specific the IL6 gene differentially in response to LPS or IL1. Cell Immunol. 122, 493–503 (1989).
Qu, D., Liu, J., Lau, C. W. & Huang, Y. IL-6 in diabetes and cardiovascular issues. Br. J. Pharmacol. 171, 3595–3603 (2014).
Butts, B., Gary, R. A., Dunbar, S. B. & Butler, J. The significance of NLRP3 inflammasome in coronary heart failure. J. Card. Fail. 21, 586–593 (2015).
Abbate, A. et al. Interleukin-1 and the inflammasome as therapeutic targets in heart problems. Circ. Res. 126, 1260–1280 (2020).
Seropian, I. M., Toldo, S., Van Tassell, B. W. & Abbate, A. Anti-inflammatory methods for ventricular transforming following ST-segment elevation acute myocardial infarction. J. Am. Coll. Cardiol. 63, 1593–1603 (2014).
Tall, A. R. & Bornfeldt, Ok. E. Inflammasomes and atherosclerosis: a combined image. Circ. Res. 132, 1505–1520 (2023).
Robbie, L. & Libby, P. Irritation and atherothrombosis. Ann. N. Y. Acad. Sci. 947, 167–179 (2001).
Liberale, L. et al. Plasma ranges of myeloperoxidase and resistin independently predict mortality in dialysis sufferers. Eur. J. Intern. Med. 129, 87–92 (2024).
Raj, D. S. et al. Soluble CD14 ranges, interleukin 6, and mortality amongst prevalent hemodialysis sufferers. Am. J. Kidney Dis. 54, 1072–1080 (2009).
Raj, D. S., Shah, V. O., Rambod, M., Kovesdy, C. P. & Kalantar-Zadeh, Ok. Affiliation of soluble endotoxin receptor CD14 and mortality amongst sufferers present process hemodialysis. Am. J. Kidney Dis. 54, 1062–1071 (2009).
Kalantar-Zadeh, Ok., Kopple, J. D., Humphreys, M. H. & Block, G. Evaluating end result predictability of markers of malnutrition-inflammation advanced syndrome in haemodialysis sufferers. Nephrol. Dial. Transpl. 19, 1507–1519 (2004).
Kalantar-Zadeh, Ok. et al. Impact of malnutrition-inflammation advanced syndrome on EPO hyporesponsiveness in upkeep hemodialysis sufferers. Am. J. Kidney Dis. 242, 761–773 (2003).
Chertow, G. M. et al. Results of selonsertib in sufferers with diabetic kidney illness. J. Am. Soc. Nephrol. 30, 1980–1990 (2019).
Heerspink, H. J. L. et al. Selonsertib in sufferers with diabetic kidney illness: a part 2b randomized lively run-in medical trial. J. Am. Soc. Nephrol. 35, 1726–1736 (2024).
Brosius, F. C., Tuttle, Ok. R. & Kretzler, M. JAK inhibition within the therapy of diabetic kidney illness. Diabetologia 59, 1624–1627 (2016).
Tuttle, Ok. R. et al. JAK1/JAK2 inhibition by baricitinib in diabetic kidney illness: outcomes from a Section 2 randomized managed medical trial. Nephrol. Dial. Transpl. 33, 1950–1959 (2018).
US Nationwide Library of Drugs. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT05237388 (2026).
Meier, M. et al. Deletion of protein kinase C-beta isoform in vivo reduces renal hypertrophy however not albuminuria within the streptozotocin-induced diabetic mouse mannequin. Diabetes 56, 346–354 (2006).
Tuttle, Ok. R. et al. The impact of ruboxistaurin on nephropathy in sort 2 diabetes. Diabetes Care 28, 2686–2690 (2005).
Tuttle, Ok. R., McGill, J. B., Haney, D. J., Lin, T. E. & Anderson, P. W. Kidney outcomes in long-term research of ruboxistaurin for diabetic eye illness. Clin. J. Am. Soc. Nephrol. 2, 631–636 (2006).
Zoja, C., Benigni, A. & Remuzzi, G. The Nrf2 pathway within the development of renal illness. Nephrol. Dial. Transpl. 29, i19–i24 (2014).
Nezu, M., Suzuki, N. & Yamamoto, M. Focusing on the KEAP1-NRF2 system to stop kidney illness development. Am. J. Nephrol. 45, 473–483 (2017).
Pergola, P. E. et al. Bardoxolone methyl and kidney operate in CKD with sort 2 diabetes. N. Engl. J. Med. 365, 327–336 (2011).
de Zeeuw, D. et al. Bardoxolone methyl in sort 2 diabetes and stage 4 continual kidney illness. N. Engl. J. Med. 369, 2492–2503 (2013).
Chin, M. P. et al. Mechanisms contributing to hostile cardiovascular occasions in sufferers with sort 2 diabetes mellitus and stage 4 continual kidney illness handled with bardoxolone methyl. Am. J. Nephrol. 39, 499–508 (2014).
Chin, M. P. et al. Danger components for coronary heart failure in sufferers with sort 2 diabetes mellitus and stage 4 continual kidney illness handled with bardoxolone methyl. J. Card. Fail. 20, 953–958 (2014).
Nangaku, M. et al. Randomized medical trial on the impact of bardoxolone methyl on GFR in diabetic kidney illness sufferers (TSUBAKI Research). Kidney Int. Rep. 5, 879–890 (2020).
Nangaku, M. et al. Randomized, double-blind, placebo-controlled part 3 research of bardoxolone methyl in sufferers with diabetic kidney illness: design and baseline traits of the AYAME research. Nephrol. Dial. Transpl. 38, 1204–1216 (2023).
Donate-Correa, J. et al. Repurposing medication for extremely prevalent ailments: pentoxifylline, an outdated drug and a brand new alternative for diabetic kidney illness. Clin. Kidney J. 15, 2200–2213 (2022).
Chen, Y. M. et al. Pentoxifylline suppresses renal tumour necrosis factor-α and ameliorates experimental crescentic glomerulonephritis in rats. Nephrol. Dial. Transpl. 19, 1106–1115 (2004).
DiPetrillo, Ok. & Gesek, F. A. Pentoxifylline ameliorates renal tumor necrosis issue expression, sodium retention, and renal hypertrophy in diabetic rats. Am. J. Nephrol. 24, 352–359 (2004).
Lin, S. L., Chen, Y. M., Chiang, W. C., Wu, Ok. D. & Tsai, T. J. Impact of pentoxifylline along with losartan on proteinuria and GFR in CKD: a 12-month randomized trial. Am. J. Kidney Dis. 52, 464–474 (2008).
Navarro-González, J. F. et al. Impact of pentoxifylline on renal operate and urinary albumin excretion in sufferers with diabetic kidney illness: the PREDIAN trial. J. Am. Soc. Nephrol. 26, 220–229 (2015).
Kuo, Ok. L. et al. Add-on protecting impact of pentoxifylline in superior continual kidney illness handled with renin-angiotensin-aldosterone system blockade — a nationwide database evaluation. Sci. Rep. 5, 17150 (2015).
Leehey, D. J. et al. Pentoxifylline in diabetic kidney illness (VA PTXRx): protocol for a practical randomised managed trial. BMJ Open. 11, e053019 (2021).
Leehey, D. J. & Agarwal, R. Is there a job for pentoxifylline in diabetic kidney illness? A mini evaluate. Am. J. Kidney Dis. 87, 835–840 (2026).
Ridker, P. M. et al. Antiinflammatory remedy with canakinumab for atherosclerotic illness. N. Engl. J. Med. 377, 1119–1131 (2017).
Ridker, P. M. et al. Relationship of C-reactive protein discount to cardiovascular occasion discount following therapy with canakinumab: a secondary evaluation from the CANTOS randomised managed trial. Lancet 391, 319–328 (2018).
Ridker, P. M., MacFadyen, J. G., Thuren, T. & Libby, P. Residual inflammatory danger related to interleukin-18 and interleukin-6 after profitable interleukin-1β inhibition with canakinumab: additional rationale for the event of focused anti-cytokine therapies for the therapy of atherothrombosis. Eur. Coronary heart J; 41, 2153–2163 (2020).
Ridker, P. M. et al. Inhibition of Interleukin-1β by canakinumab and cardiovascular outcomes in sufferers with continual kidney illness. J. Am. Coll. Cardiol. 71, 2405–2414 (2018).
Ridker, P. M. et al. Impact of interleukin-1β inhibition with canakinumab on incident lung most cancers in sufferers with atherosclerosis: exploratory outcomes from a randomised, double-blind, placebo-controlled trial. Lancet 390, 1833–1842 (2017).
Nowak, Ok. L. et al. IL-1 inhibition and vascular operate in CKD. J. Am. Soc. Nephrol. 28, 971–980 (2017).
Ridker, P. M. et al. IL-6 inhibition with ziltivekimab in sufferers at excessive atherosclerotic danger (RESCUE): a double-blind, randomised, placebo-controlled, part 2 trial. Lancet 397, 2060–2069 (2021).
Ridker, P. M. et al. Rationale, design, and baseline medical traits of the Ziltivekimab Cardiovascular Outcomes Trial: interleukin-6 inhibition and atherosclerotic occasion fee discount. JAMA Cardiol. 11, 89–97 (2026).
US Nationwide Library of Drugs. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT06118281 (2026).
US Nationwide Library of Drugs. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT05636176 (2026).
US Nationwide Library of Drugs. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT06200207 (2026)
Chertow, G. M. et al. IL-6 inhibition with clazakizumab in sufferers receiving upkeep dialysis: a randomized part 2b trial. Nat. Med. 30, 2328–2336 (2024).
Neuen, B. L. et al. Results of clazakizumab on anemia and iron metabolism in sufferers with kidney failure. J. Am. Soc. Nephrol. 36, 923–925 (2025).
Pergola, P. E. et al. Impact of ziltivekimab on determinants of hemoglobin in sufferers with CKD stage 3–5: an evaluation of a randomized trial (RESCUE). J. Am. Soc. Nephrol. 35, 74–84 (2024).
US Nationwide Library of Drugs. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT05485961 (2026)
US Nationwide Library of Drugs. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT06362759 (2026).
O’Connell, T. D., Mason, R. P., Budoff, M. J., Navar, A. M. & Shearer, G. C. Mechanistic insights into cardiovascular safety for omega-3 fatty acids and their bioactive lipid metabolites. Eur. Coronary heart J. Suppl. 22, J3–J20 (2020).
Lok, C. E. et al. Fish-oil supplementation and cardiovascular occasions in sufferers receiving hemodialysis. N. Engl. J. Med. 394, 128–137 (2026).
Xia, X. et al. Mechanisms and therapeutic potential of colchicine in atherosclerotic heart problems. Nat. Cardiovasc. Res. 5, 404–422 (2026).
Tardif, J. C. et al. Efficacy and security of low-dose colchicine after myocardial infarction. N. Engl. J. Med. 381, 2497–2505 (2019).
Nidorf, S. M. et al. Colchicine in sufferers with continual coronary illness. N. Engl. J. Med. 383, 1838–1847 (2020).
Jolly, S. S. et al. Colchicine in acute myocardial infarction. N. Engl. J. Med. 392, 633–642 (2025).
Laudani, C., Abbate, A., Angiolillo, D. J. & Galli, M. CLEAR outcomes, cloudy influence: colchicine’s impartial function in ST-segment elevation myocardial infarction. Eur. Coronary heart J. Cardiovasc. Pharmacother. 11, 215–217 (2025).
Tardif, J. C. & Kouz, S. Efficacy and security of colchicine and spironolactone after myocardial infarction: the CLEAR-SYNERGY trial in perspective. Eur. Coronary heart J. Acute Cardiovasc. Care 13, 843–844 (2024).
d’Entremont, M. A. et al. Colchicine for secondary prevention of vascular occasions: a meta-analysis of trials. Eur. Coronary heart J. 46, 2564–25751 (2025).
Mangoni, A. A., Hulin, J. A. & Tommasi, S. Latest advances in methotrexate pharmacology and potential therapeutic makes use of in age-related cardiometabolic and neurodegenerative ailments. Pharmacol. Rev. 78, 100147 (2026).
Fedorchenko, Y., Khojakulova, U., Permenov, B. A., Fedorchenko, M. & Usen, A. Cardiometabolic danger and vascular adjustments in rheumatic ailments. Rheumatol. Int. 46, 93 (2026).
Ridker, P. M. et al. Low-dose methotrexate for the prevention of atherosclerotic occasions. N. Engl. J. Med. 380, 752–762 (2019).
Solomon, D. H. et al. Hostile results of low-dose methotrexate: a randomized trial. Ann. Intern. Med. 172, 369–380 (2020).
Lamkanfi, M. et al. Glyburide inhibits the cryopyrin/Nalp3 inflammasome. J. Cell Biol. 187, 61–70 (2009).
Hill, J. R. et al. Sulfonylureas as concomitant insulin secretagogues and NLRP3 inflammasome inhibitors. ChemMedChem 12, 1449–1457 (2017).
Li, N. et al. Latest progress and prospects of small molecules for NLRP3 inflammasome inhibition. J. Med. Chem. 66, 14447–14473 (2023).
Su, M., Wang, W., Liu, F. & Li, H. Latest progress on the invention of NLRP3 inhibitors and their therapeutic potential. Curr. Med. Chem. 28, 569–582 (2021).
No writer group KDIGO 2024 medical apply guideline for the analysis and administration of continual kidney illness. Kidney Int. 105, S117–S314 (2024).
Jones, D. W. et al. AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Analysis and Administration of Excessive Blood Strain in Adults: a report of the American Faculty of Cardiology/American Coronary heart Affiliation Joint Committee on Medical Observe Pointers. Circulation 152, e114–e218 (2025).
Heidenreich, P. A. et al. AHA/ACC/HFSA Guideline for the Administration of Coronary heart Failure: a report of the American Faculty of Cardiology/American Coronary heart Affiliation Joint Committee on Medical Observe Pointers. Circulation 145, e895–e1032 (2022).
Dandona, P., Dhindsa, S., Ghanim, H. & Chaudhuri, A. Angiotensin II and irritation: the impact of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade. J. Hum. Hypertens. 21, 20–27 (2007).
Crowley, S. D. & Rudemiller, N. P. Immunologic results of the renin-angiotensin system. J. Am. Soc. Nephrol. 28, 1350–1361 (2017).
Awad, Ok. et al. Impact of the renin-angiotensin system inhibitors on inflammatory markers: a scientific evaluate and meta-analysis of randomized managed trials. Mayo Clin. Proc. 97, 1808–1823 (2022).
Sola, S. et al. Irbesartan and lipoic acid enhance endothelial operate and scale back markers of irritation within the metabolic syndrome: outcomes of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) research. Circulation 111, 343–348 (2005).
Rosei, E. A. et al. Results of candesartan cilexetil and enalapril on inflammatory markers of atherosclerosis in hypertensive sufferers with non-insulin-dependent diabetes mellitus. J. Hypertens. 23, 435–444 (2005).
Wang, D. et al. The impact of sodium-glucose cotransporter 2 inhibitors on biomarkers of irritation: a scientific evaluate and meta-analysis of randomized managed trials. Entrance. Pharmacol. 13, 1045235 (2022).
Kim, S. R. et al. SGLT2 inhibition modulates NLRP3 inflammasome exercise by way of ketones and insulin in diabetes with heart problems. Nat. Commun. 11, 2127 (2020).
Heerspink, H. J. L. et al. Canagliflozin reduces irritation and fibrosis biomarkers: a possible mechanism of motion for helpful results of SGLT2 inhibitors in diabetic kidney illness. Diabetologia 62, 1154–1166 (2019).
Tahara, A. et al. Results of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, irritation, and weight problems in sort 2 diabetic mice. Eur. J. Pharmacol. 715, 246–255 (2013).
Xu, L. et al. SGLT2 inhibition by empagliflozin promotes fats utilization and browning and attenuates irritation and insulin resistance by polarizing M2 macrophages in diet-induced overweight mice. EBioMedicine 20, 137–149 (2017).
Birnbaum, Y., Bajaj, M., Yang, H. C. & Ye, Y. Mixed SGLT2 and DPP4 inhibition reduces the activation of the Nlrp3/ASC inflammasome and attenuates the event of diabetic nephropathy in mice with sort 2 diabetes. Cardiovasc. Medication Ther. 32, 135–145 (2018).
Ye, Y., Bajaj, M., Yang, H. C., Perez-Polo, J. R. & Birnbaum, Y. SGLT-2 inhibition with dapagliflozin reduces the activation of the Nlrp3/ASC inflammasome and attenuates the event of diabetic cardiomyopathy in mice with sort 2 diabetes. Additional augmentation of the consequences with saxagliptin, a DPP4 inhibitor. Cardiovasc. Medication Ther. 31, 119–132 (2017).
Panchapakesan, U. et al. Results of SGLT2 inhibition in human kidney proximal tubular cells-renoprotection in diabetic nephropathy? PLoS ONE 8, e54442 (2013).
Tang, L. et al. Dapagliflozin slows the development of the renal and liver fibrosis related to sort 2 diabetes. Am. J. Physiol. Endocrinol. Metab. 313, E563–E576 (2017).
Ashrafizadeh, M., Yaribeygi, H., Atkin, S. L. & Sahebkar, A. Results of newly launched antidiabetic medication on autophagy. Diabetes Metab. Syndr. 13, 2445–2449 (2019).
No writer group KDIGO 2022 medical apply guideline for diabetes administration in continual kidney illness. Kidney Int. 102, S1–S127 (2022).
Solomon, S. D. et al. Finerenone in coronary heart failure with mildly diminished or preserved ejection fraction. N. Engl. J. Med. 2024, 1475–1485 (2024).
Vaduganathan, M. et al. Finerenone in coronary heart failure and continual kidney illness with sort 2 diabetes: FINE-HEART pooled evaluation of cardiovascular, kidney and mortality outcomes. Nat. Med. 30, 3758–3764 (2024).
Neuen, B. L. et al. Efficacy and security of finerenone in sufferers with continual kidney illness: a person participant knowledge pooled evaluation (INFINITY). Lancet 407, 2375–2386 (2026).
Fraccarollo, D. et al. Deletion of cardiomyocyte mineralocorticoid receptor ameliorates hostile transforming after myocardial infarction. Circulation 123, 400–408 (2011).
Lv, R. et al. Cardiovascular-renal protecting impact and molecular mechanism of finerenone in sort 2 diabetic mellitus. Entrance. Endocrinol. 14, 1125693 (2023).
Sattar, N. et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in sufferers with sort 2 diabetes: a scientific evaluate and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 9, 653–662 (2021).
Badve, S. V. et al. Results of GLP-1 receptor agonists on kidney and heart problems outcomes: a meta-analysis of randomised managed trials. Lancet Diabetes Endocrinol. 13, 15–28 (2025).
Lee, M. M. Y. et al. Cardiovascular and kidney outcomes and mortality with long-acting injectable and oral glucagon-like peptide 1 receptor agonists in people with sort 2 diabetes: a scientific evaluate and meta-analysis of randomized trials. Diabetes Care 48, 846–859 (2025).
Perkovic, V. et al. Results of semaglutide on continual kidney illness in sufferers with sort 2 diabetes. N. Engl. J. Med. 391, 109–121 (2024).
Pratley, R. E. et al. Results of semaglutide on coronary heart failure outcomes in diabetes and continual kidney illness within the circulation trial. J. Am. Coll. Cardiol. 84, 1615–1628 (2024).
Apperloo, E. M. et al. Semaglutide in sufferers with chubby or weight problems and continual kidney illness with out diabetes: a randomized double-blind placebo-controlled medical trial. Nat. Med. 31, 278–285 (2025).
Kosiborod, M. N. et al. Semaglutide in sufferers with coronary heart failure with preserved ejection fraction and weight problems. N. Engl. J. Med. 389, 1069–1084 (2023).
Packer, M. et al. Tirzepatide for coronary heart failure with preserved ejection fraction and weight problems. N. Engl. J. Med. 392, 427–437 (2025).
Ceriello, A. et al. Glucagon-like peptide 1 reduces endothelial dysfunction, irritation, and oxidative stress induced by each hyperglycemia and hypoglycemia in sort 1 diabetes. Diabetes Care 36, 2346–2350 (2013).
Ceriello, A. et al. Simultaneous GLP-1 and insulin administration acutely enhances their vasodilatory, antiinflammatory, and antioxidant motion in sort 2 diabetes. Diabetes Care 37, 1938–1943 (2014).
Wong, C. Ok. et al. Central glucagon-like peptide 1 receptor activation inhibits Toll-like receptor agonist-induced irritation. Cell Metab. 36, 130–143 (2024).
Sourris, Ok. C. et al. Glucagon-like peptide-1 receptor signaling modifies the extent of diabetic kidney illness by way of dampening the receptor for superior glycation finish products-induced irritation. Kidney Int. 105, 132–149 (2024).
Cherney, D. Z. I. et al. Rationale, design and baseline traits of REMODEL, a mechanism-of-action trial with semaglutide in individuals with sort 2 diabetes and continual kidney illness. Nephrol. Dial. Transpl. 40, 2182–2192 (2025).
Rovin, B. H. et al. Efficacy and security of sparsentan versus irbesartan in sufferers with IgA nephropathy (PROTECT): 2-year outcomes from a randomised, active-controlled, part 3 trial. Lancet 402, 2077–2090 (2023).
Rheault, M. N. et al. Sparsentan versus irbesartan in focal segmental glomerulosclerosis. N. Engl. J. Med. 389, 2436–2445 (2023).
Heerspink, H. J. L. et al. Atrasentan and renal occasions in sufferers with sort 2 diabetes and continual kidney illness (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet 393, 1937–1947 (2019).
US Nationwide Library of Drugs. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT04724837 (2024).
Heerspink, H. J. L. et al. Zibotentan together with dapagliflozin in contrast with dapagliflozin in sufferers with continual kidney illness (ZENITH-CKD): a multicentre, randomised, active-controlled, part 2b, medical trial. Lancet 402, 2004–2017 (2023).
Wort, S. J. et al. Synergistic induction of endothelin-1 by tumor necrosis issue α and interferon γ is because of enhanced NF-κB binding and histone acetylation at particular κB websites. J. Biol. Chem. 284, 24297–24305 (2009).
Barton, M. Reversal of proteinuric renal illness and the rising function of endothelin. Nat. Clin. Pract. Nephrol. 4, 490–501 (2008).
Saleh, M. A., Pollock, J. S. & Pollock, D. M. Distinct actions of endothelin A-selective versus mixed endothelin A/B receptor antagonists in early diabetic kidney illness. J. Pharmacol. Exp. Ther. 338, 263–270 (2011).
Saleh, M. A., Boesen, E. I., Pollock, J. S., Savin, V. J. & Pollock, D. M. Endothelin-1 will increase glomerular permeability and irritation unbiased of blood strain within the rat. Hypertension 56, 942–949 (2010).
Rivera-Gonzalez, O., Wilson, N. A., Coats, L. E., Taylor, E. B. & Velocity, J. S. Endothelin receptor antagonism improves glucose dealing with, dyslipidemia, and adipose tissue irritation in overweight mice. Clin. Sci. 135, 1773–1789 (2021).
Koh, Ok. Ok. et al. Pleiotropic results of angiotensin II receptor blocker in hypertensive sufferers. J. Am. Coll. Cardiol. 42, 905–910 (2003).
Sonmez, A. et al. Results of losartan therapy on T-cell actions and plasma leptin concentrations in major hypertension. J. Renin Angiotensin Aldosterone Syst. 2, 112–116 (2001).
Lopez Santi, R. G. et al. Results of an angiotensin-converting enzyme inhibitor (ramipril) on inflammatory markers in secondary prevention sufferers: RAICES research. Coron. Artery Dis. 16, 423–429 (2005).
Koh, Ok. Ok. et al. Additive helpful results of losartan mixed with simvastatin within the therapy of hypercholesterolemic, hypertensive sufferers. Circulation 110, 3687–3692 (2004).
Schieffer, B. et al. Comparative results of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of irritation and platelet aggregation in sufferers with coronary artery illness. J. Am. Coll. Cardiol. 44, 362–368 (2004).
Gamboa, J. L. et al. Comparative results of angiotensin-converting enzyme inhibition and angiotensin-receptor blockade on irritation throughout hemodialysis. J. Am. Soc. Nephrol. 23, 334–342 (2012).
Xu, J., Kitada, M., Ogura, Y., Liu, H. & Koya, D. Dapagliflozin restores impaired autophagy and suppresses irritation in excessive glucose-treated HK-2 Cells. Cells 10, 1457 (2021).
Dekkers, C. C. J. et al. Results of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular harm markers. Diabetes Obes. Metab. 20, 1988–1993 (2018).
Niu, Y. et al. Intragastric and atomized administration of canagliflozin inhibit inflammatory cytokine storm in lipopolysaccharide-treated sepsis in mice: a possible COVID-19 therapy. Int. Immunopharmacol. 96, 107773 (2021).
Hasan, R. et al. Canagliflozin ameliorates renal oxidative stress and irritation by stimulating AMPK-Akt-eNOS pathway within the isoprenaline-induced oxidative stress mannequin. Sci. Rep. 10, 14659 (2020).
Sen, T. et al. Results of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 within the CANVAS trial. Diabetologia 64, 2147–2158 (2021).
Lee, N. et al. Anti-inflammatory results of empagliflozin and gemigliptin on LPS-stimulated macrophage by way of the IKK/NF-κB, MKK7/JNK, and JAK2/STAT1 signalling pathways. J. Immunol. Res. 2021, 9944880 (2021).
Hattori, S. Anti-inflammatory results of empagliflozin in sufferers with sort 2 diabetes and insulin resistance. Diabetol. Metab. Syndr. 10, 93 (2018).
Gotzmann, M. et al. Empagliflozin reduces interleukin-6 ranges in sufferers with coronary heart failure. J. Clin. Med. 12, 4458 (2023).
La Grotta, R. et al. Anti-inflammatory impact of SGLT-2 inhibitors by way of uric acid and insulin. Cell Mol. Life Sci. 79, 273 (2022).
Grune, J. et al. Selective mineralocorticoid receptor cofactor modulation as molecular foundation for finerenone’s antifibrotic exercise. Hypertension 71, 599–608 (2018).
Barrera-Chimal, J. et al. The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal harm by way of macrophage interleukin-4 receptor signaling. Kidney Int. 93, 1344–1355 (2018).
Track, J. et al. Impact of finerenone on urinary protein and inflammatory issue ranges in sort 2 diabetes mellitus sufferers with diabetic kidney illness. PLoS ONE 20, e0329965 (2025).
Tuttle, Ok. R. et al. Mechanistic results of semaglutide on kidney illness in sort 2 diabetes: the REMODEL trial. J. Am. Soc. Nephrol. https://doi.org/10.1681/ASN.2025fdqxb4qe (2025).
Chaudhuri, A. et al. Exenatide exerts a potent antiinflammatory impact. J. Clin. Endocrinol. Metab. 97, 198–207 (2012).
Zimmer, S., Grebe, A. & Latz, E. Hazard signaling in atherosclerosis. Circ. Res. 116, 323–340 (2015).
